{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:02:26Z","timestamp":1790946146588,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Imatinib (IM), targeting of BCR-ABL1 tyrosine kinase, is currently one of the first-line choices in the treatment of chronic myeloid leukemia (CML). This study aims to explore the molecular mechanisms underlying IM resistance in CML treatment. 108 CML patients were recruited and grouped according to their sensitivity to IM as the responder group (N\u2009=\u200966) and the non-responder group (N\u2009=\u200942). Real-time quantitative PCR (RT-qPCR) was performed to evaluate the expression of candidate circular RNAs (circRNAs), microRNA (miRNAs) and messenger RNA (mRNAs). No significant difference was noted regarding demographic and clinicopathological characteristics between the responder group and the non-responder group. The expression of circ_0080145, circ_0051886 and ABL1 mRNA was significantly increased, while the expression of miR-203 and miR-637 was decreased in the non-responder group as compared with the responders. By using in-silicon analysis, it was predicted that circ_0080145 and circ_0051886 targeted miR-203 and miR-637 respectively, and ABL1 was found to be shared direct target gene of miR-203 and miR-637. Ectopic over-expression of circ_0080145 and circ_0051886 respectively reduced the expression of miR-203 and miR-637. The expression of ABL1 mRNA\/protein was most upregulated in culture cells co-transfected with circ_0080145 and circ_0051886 as compared with those cells individually transfected. This study established the signaling pathways of circ_0080145\/miR-203\/ABL1 and circ 0051886\/miR-637\/ABL1. The deregulation of circ_0080145 and circ_0051886 is, at least partially, responsible for the development of IM chemoresistance in CML by regulating expression of ABL1 via modulating expression of miR-203 and miR-637.<\/jats:p>","DOI":"10.1186\/s10020-021-00395-z","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T11:03:16Z","timestamp":1636974196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145\/miR-203\/ABL1 and circ 0051886\/miR-637\/ABL1"],"prefix":"10.1186","volume":"27","author":[{"given":"Yao-hua","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-739X","authenticated-orcid":false,"given":"Zhong-yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"issue":"4","key":"395_CR1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1182\/blood-2005-05-2123","volume":"107","author":"A Aloisi","year":"2006","unstructured":"Aloisi A, Di Gregorio S, Stagno F, Guglielmo P, Mannino F, Sormani MP, Bruzzi P, Gambacorti-Passerini C, Saglio G, Venuta S, Giustolisi R, Messina A, Vigneri P. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood. 2006;107(4):1591\u20138.","journal-title":"Blood"},{"issue":"Suppl 4","key":"395_CR2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/annonc\/mdp143","volume":"20","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Dreyling M, Group EGW. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):105\u20137.","journal-title":"Ann Oncol"},{"key":"395_CR3","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1158\/1078-0432.CCR-08-1818","volume":"15","author":"E Bandres","year":"2009","unstructured":"Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, Zarate R, Diaz-Gonzalez JA, Ramirez N, Sola JJ, Jimenez P, Rodriguez J, Garcia-Foncillas J. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res. 2009;15:2281\u201390.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"395_CR4","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","volume":"17","author":"E Beillard","year":"2003","unstructured":"Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u201creal-time\u201d quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2014a Europe against cancer program. Leukemia. 2003;17(12):2474\u201386.","journal-title":"Leukemia"},{"key":"395_CR5","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/stem.741","volume":"29","author":"N Bitarte","year":"2011","unstructured":"Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM, Fortes P, Garcia-Foncillas J. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. 2011;29:1661\u201371.","journal-title":"Stem Cells"},{"key":"395_CR6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","volume":"25","author":"D Bixby","year":"2011","unstructured":"Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia. 2011;25:7\u201322.","journal-title":"Leukemia"},{"key":"395_CR7","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1038\/bcj.2016.81","volume":"6","author":"A Bonizzato","year":"2016","unstructured":"Bonizzato A, Gaffo E, Te Kronnie G, Bortoluzzi S. CircRNAs in hematopoiesis and hematological malignancies. Blood Cancer J. 2016;6:e483.","journal-title":"Blood Cancer J"},{"key":"395_CR8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","volume":"13","author":"MJ Bueno","year":"2008","unstructured":"Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernandez-Piqueras J, Malumbres M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13:496\u2013506.","journal-title":"Cancer Cell"},{"key":"395_CR9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ccell.2016.03.013","volume":"29","author":"MJ Bueno","year":"2016","unstructured":"Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernandez-Piqueras J, Malumbres M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2016;29:607\u20138.","journal-title":"Cancer Cell"},{"key":"395_CR10","doi-asserted-by":"crossref","first-page":"117255","DOI":"10.1016\/j.lfs.2020.117255","volume":"243","author":"HX Cao","year":"2020","unstructured":"Cao HX, Miao CF, Sang LN, Huang YM, Zhang R, Sun L, Jiang ZX. Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy by sponging miR-34a-5p in chronic myeloid leukemia. Life Sci. 2020;243:117255.","journal-title":"Life Sci"},{"issue":"1","key":"395_CR11","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/s41598-019-38672-x","volume":"9","author":"C Chandrasekhar","year":"2019","unstructured":"Chandrasekhar C, Kumar PS, Sarma PVGK. Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients. Sci Rep. 2019;9(1):2412.","journal-title":"Sci Rep"},{"key":"395_CR12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-016-0370-2","volume":"10","author":"Y Dong","year":"2017","unstructured":"Dong Y, He D, Peng Z, Peng W, Shi W, Wang J, Li B, Zhang C, Duan C. Circular RNAs in cancer: an emerging key player. J Hematol Oncol. 2017;10:2.","journal-title":"J Hematol Oncol"},{"key":"395_CR13","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, Investigators I. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"395_CR14","first-page":"6996","volume":"233","author":"XJ Du","year":"2018","unstructured":"Du XJ, Lu JM, Sha Y. MiR-181a inhibits vascular inflammation induced by ox-LDL via targeting TLR4 in human macrophages. J Cell Physiol. 2018;233:6996\u20137003.","journal-title":"J Cell Physiol"},{"key":"395_CR15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4149\/neo_2018_181129N908","volume":"67","author":"XQ Feng","year":"2020","unstructured":"Feng XQ, Nie SM, Huang JX, Li TL, Zhou JJ, Wang W, Zhuang LK, Meng FJ. Circular RNA circHIPK3 serves as a prognostic marker to promote chronic myeloid leukemia progression. Neoplasma. 2020;67:171\u20137.","journal-title":"Neoplasma"},{"key":"395_CR16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","volume":"63","author":"PJ Fialkow","year":"1977","unstructured":"Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage. Am J Med. 1977;63:125\u201330.","journal-title":"Am J Med"},{"issue":"8","key":"395_CR17","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","volume":"95","author":"S Flamant","year":"2010","unstructured":"Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, Guilhot F, Turhan AG, Rasko JE. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica. 2010;95(8):1325\u201333.","journal-title":"Haematologica"},{"key":"395_CR18","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/carcin\/bgp250","volume":"31","author":"M Furuta","year":"2010","unstructured":"Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010;31:766\u201376.","journal-title":"Carcinogenesis"},{"key":"395_CR19","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876\u201380.","journal-title":"Science"},{"key":"395_CR20","first-page":"837","volume":"21","author":"Q He","year":"2017","unstructured":"He Q, Wang CM, Qin JY, Zhang YJ, Xia DS, Chen X, Guo SZ, Zhao XD, Guo QY, Lu CZ. Effect of miR-203 expression on myocardial fibrosis. Eur Rev Med Pharmacol Sci. 2017;21:837\u201342.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"395_CR21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.canlet.2014.10.006","volume":"356","author":"O Hershkovitz-Rokah","year":"2015","unstructured":"Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O, Granot G. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. Cancer Lett. 2015;356:597\u2013605.","journal-title":"Cancer Lett"},{"issue":"11","key":"395_CR22","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, La Ros\u00e9e P, M\u00fcller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16(11):2190\u20136.","journal-title":"Leukemia"},{"key":"395_CR23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.lungcan.2016.04.017","volume":"97","author":"H Hu","year":"2016","unstructured":"Hu H, Xu Z, Li C, Xu C, Lei Z, Zhang HT, Zhao J. MiR-145 and miR-203 represses TGF-beta-induced epithelial-mesenchymal transition and invasion by inhibiting SMAD3 in non-small cell lung cancer cells. Lung Cancer. 2016;97:87\u201394.","journal-title":"Lung Cancer"},{"issue":"37","key":"395_CR24","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","volume":"107","author":"M J\u00e4r\u00e5s","year":"2010","unstructured":"J\u00e4r\u00e5s M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M, Lassen C, Olofsson T, Bjerrum OW, Richter J, Fioretos T. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA. 2010;107(37):16280\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"395_CR25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gene.2014.03.049","volume":"542","author":"D Joshi","year":"2014","unstructured":"Joshi D, Chandrakala S, Korgaonkar S, Ghosh K, Vundinti BR. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR\/ABL positive CML patients. Gene. 2014;542:109\u201312.","journal-title":"Gene"},{"key":"395_CR26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.20452\/pamw.843","volume":"119","author":"K Lewandowski","year":"2009","unstructured":"Lewandowski K, Warzocha K, Hellmann A, Skotnicki A, Prejzner W, Foryciarz K, Sacha T, Gniot M, Majewski M, Solarska I, Nowak G, Wasag B, Kobelski M, Scibiorski C, Siemiatkowski M, Lewandowska M, Komarnicki M. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study. Pol Arch Med Wewn. 2009;119:789\u201394.","journal-title":"Pol Arch Med Wewn"},{"key":"395_CR27","doi-asserted-by":"crossref","first-page":"e61858","DOI":"10.1371\/journal.pone.0061858","volume":"8","author":"Y Li","year":"2013","unstructured":"Li Y, Yuan Y, Tao K, Wang X, Xiao Q, Huang Z, Zhong L, Cao W, Wen J, Feng W. Inhibition of BCR\/ABL protein expression by miR-203 sensitizes for imatinib mesylate. PLoS ONE. 2013;8:e61858.","journal-title":"PLoS ONE"},{"key":"395_CR28","doi-asserted-by":"crossref","first-page":"e0174436","DOI":"10.1371\/journal.pone.0174436","volume":"12","author":"Y Li","year":"2017","unstructured":"Li Y, Dong Y, Huang Z, Kuang Q, Wu Y, Li Y, Li M. Computational identifying and characterizing circular RNAs and their associated genes in hepatocellular carcinoma. PLoS ONE. 2017;12:e0174436.","journal-title":"PLoS ONE"},{"key":"395_CR29","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bbrc.2018.08.154","volume":"504","author":"J Liu","year":"2018","unstructured":"Liu J, Kong F, Lou S, Yang D, Gu L. Global identification of circular RNAs in chronic myeloid leukemia reveals hsa_circ_0080145 regulates cell proliferation by sponging miR-29b. Biochem Biophys Res Commun. 2018;504:660\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"395_CR30","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"key":"395_CR31","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","volume":"22","author":"CM Lucas","year":"2008","unstructured":"Lucas CM, Wang L, Austin GM, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008;22:1963\u20136.","journal-title":"Leukemia"},{"key":"395_CR32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11899-012-0152-z","volume":"8","author":"K Machova Polakova","year":"2013","unstructured":"Machova Polakova K, Koblihova J, Stopka T. Role of epigenetics in chronic myeloid leukemia. Curr Hematol Malig Rep. 2013;8:28\u201336.","journal-title":"Curr Hematol Malig Rep"},{"key":"395_CR33","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00277-018-3296-7","volume":"97","author":"C Musolino","year":"2018","unstructured":"Musolino C, Oteri G, Allegra A, Mania M, D\u2019Ascola A, Avenoso A, Innao V, Allegra AG, Campo S. Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw. Ann Hematol. 2018;97:1259\u201369.","journal-title":"Ann Hematol"},{"key":"395_CR34","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1038\/ncomms9039","volume":"6","author":"K Naka","year":"2015","unstructured":"Naka K, Jomen Y, Ishihara K, Kim J, Ishimoto T, Bae EJ, Mohney RP, Stirdivant SM, Oshima H, Oshima M, Kim DW, Nakauchi H, Takihara Y, Kato Y, Ooshima A, Kim SJ. Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells. Nat Commun. 2015;6:8039.","journal-title":"Nat Commun"},{"issue":"5","key":"395_CR35","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/bloodadvances.2020002973","volume":"5","author":"A Nasser","year":"2021","unstructured":"Nasser A, Hussein A, Chamba C, Yonazi M, Mushi R, Schuh A, Luzzatto L. Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania. Blood Adv. 2021;5(5):1403\u201311.","journal-title":"Blood Adv"},{"key":"395_CR36","doi-asserted-by":"crossref","first-page":"8223","DOI":"10.18632\/oncotarget.6972","volume":"7","author":"M Obayashi","year":"2016","unstructured":"Obayashi M, Yoshida M, Tsunematsu T, Ogawa I, Sasahira T, Kuniyasu H, Imoto I, Abiko Y, Xu D, Fukunaga S, Tahara H, Kudo Y, Nagao T, Takata T. microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer. Oncotarget. 2016;7:8223\u201339.","journal-title":"Oncotarget"},{"key":"395_CR37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bcmd.2018.09.002","volume":"73","author":"Y Pan","year":"2018","unstructured":"Pan Y, Lou J, Wang H, An N, Chen H, Zhang Q, Du X. CircBA9.3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels. Blood Cells Mol Dis. 2018;73:38\u201344.","journal-title":"Blood Cells Mol Dis"},{"key":"395_CR38","doi-asserted-by":"publisher","DOI":"10.3727\/096504018X15412701483326","author":"L Ping","year":"2019","unstructured":"Ping L, Jian-Jun C, Chu-Shu L, Guang-Hua L, Ming Z. High circ_100053 predicts a poor outcome for chronic myeloid leukemia and is involved in imatinib resistance. Oncol Res. 2019. https:\/\/doi.org\/10.3727\/096504018X15412701483326.","journal-title":"Oncol Res"},{"key":"395_CR39","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172\u201383.","journal-title":"Nat Rev Cancer"},{"key":"395_CR40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-8-69","volume":"8","author":"E San Jos\u00e9-En\u00e9riz","year":"2009","unstructured":"San Jos\u00e9-En\u00e9riz E, Rom\u00e1n-G\u00f3mez J, Jim\u00e9nez-Velasco A, Garate L, Martin V, Cordeu L, Vilas-Zornoza A, Rodr\u00edguez-Otero P, Calasanz MJ, Pr\u00f3sper F, Agirre X. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2009;8:69.","journal-title":"Mol Cancer"},{"key":"395_CR41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399\u2013401.","journal-title":"Science"},{"key":"395_CR42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1476-4598-8-102","volume":"8","author":"O Slaby","year":"2009","unstructured":"Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009;8:102.","journal-title":"Mol Cancer"},{"key":"395_CR43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1586\/14737140.2016.1151356","volume":"16","author":"F Stagno","year":"2016","unstructured":"Stagno F, Stella S, Spitaleri A, Pennisi MS, Di Raimondo F, Vigneri P. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. Expert Rev Anticancer Ther. 2016;16:273\u20138.","journal-title":"Expert Rev Anticancer Ther"},{"key":"395_CR44","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.7314\/APJCP.2013.14.4.2447","volume":"14","author":"QC Sun","year":"2013","unstructured":"Sun QC, Liu MB, Shen HJ, Jiang Z, Xu L, Gao LP, Ni JL, Wu SL. Inhibition by imatinib of expression of O-glycan-related glycosyltransferases and tumor-associated carbohydrate antigens in the K562 human leukemia cell line. Asian Pac J Cancer Prev. 2013;14:2447\u201351.","journal-title":"Asian Pac J Cancer Prev"},{"key":"395_CR45","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1007\/s13277-014-1790-7","volume":"35","author":"L Tian","year":"2014","unstructured":"Tian L, Li M, Ge J, Guo Y, Sun Y, Liu M, Xiao H. MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours. Tumour Biol. 2014;35:5953\u201363.","journal-title":"Tumour Biol"},{"key":"395_CR46","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1038\/cddis.2012.174","volume":"3","author":"G Viticchie","year":"2012","unstructured":"Viticchie G, Lena AM, Cianfarani F, Odorisio T, Annicchiarico-Petruzzelli M, Melino G, Candi E. MicroRNA-203 contributes to skin re-epithelialization. Cell Death Dis. 2012;3:e435.","journal-title":"Cell Death Dis"},{"key":"395_CR47","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3892\/or.2015.3909","volume":"33","author":"L Zheng","year":"2015","unstructured":"Zheng L, Jian X, Guo F, Li N, Jiang C, Yin P, Min AJ, Huang L. miR-203 inhibits arecoline-induced epithelial-mesenchymal transition by regulating secreted frizzled-related protein 4 and transmembrane-4 L six family member 1 in oral submucous fibrosis. Oncol Rep. 2015;33:2753\u201360.","journal-title":"Oncol Rep"},{"key":"395_CR48","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","volume":"6","author":"H Zhou","year":"2015","unstructured":"Zhou H, Xu R. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell. 2015;6:403\u201312.","journal-title":"Protein Cell"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-021-00395-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-021-00395-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-021-00395-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T04:54:13Z","timestamp":1726116853000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-021-00395-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1186\/s10020-021-00395-z","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]},"assertion":[{"value":"14 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}